KR100755577B1 - 타키키닌 수용체 길항제로서의 트리아졸 유도체 - Google Patents

타키키닌 수용체 길항제로서의 트리아졸 유도체 Download PDF

Info

Publication number
KR100755577B1
KR100755577B1 KR1020047017206A KR20047017206A KR100755577B1 KR 100755577 B1 KR100755577 B1 KR 100755577B1 KR 1020047017206 A KR1020047017206 A KR 1020047017206A KR 20047017206 A KR20047017206 A KR 20047017206A KR 100755577 B1 KR100755577 B1 KR 100755577B1
Authority
KR
South Korea
Prior art keywords
phenyl
formula
trifluoromethyl
benzyl
chloro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1020047017206A
Other languages
English (en)
Korean (ko)
Other versions
KR20040104634A (ko
Inventor
알버트 쿠쪼비 아메가찌
케빈 매튜 가르디니어
에릭 제임스 헴버
지안 에릭 홍
루이스 니콜라우스 정하임
브라이언 스티븐 뮐
데이비드 마이클 레믹
마이클 알란 로버트슨
케네쓰 알렌 사빈
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20040104634A publication Critical patent/KR20040104634A/ko
Application granted granted Critical
Publication of KR100755577B1 publication Critical patent/KR100755577B1/ko
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1020047017206A 2002-04-26 2003-04-22 타키키닌 수용체 길항제로서의 트리아졸 유도체 Expired - Lifetime KR100755577B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37612102P 2002-04-26 2002-04-26
US60/376,121 2002-04-26
PCT/US2003/010681 WO2003091226A1 (en) 2002-04-26 2003-04-22 Triazole derivatives as tachykinin receptor antagonists

Publications (2)

Publication Number Publication Date
KR20040104634A KR20040104634A (ko) 2004-12-10
KR100755577B1 true KR100755577B1 (ko) 2007-09-12

Family

ID=29270766

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020047017206A Expired - Lifetime KR100755577B1 (ko) 2002-04-26 2003-04-22 타키키닌 수용체 길항제로서의 트리아졸 유도체

Country Status (30)

Country Link
US (1) US7320994B2 (https=)
EP (1) EP1501809B1 (https=)
JP (1) JP4559087B2 (https=)
KR (1) KR100755577B1 (https=)
CN (1) CN1312136C (https=)
AR (1) AR039329A1 (https=)
AT (1) ATE384053T1 (https=)
AU (1) AU2003230829B8 (https=)
BR (1) BRPI0309534B8 (https=)
CA (1) CA2483159C (https=)
CR (1) CR7548A (https=)
CY (1) CY1107221T1 (https=)
DE (1) DE60318697T2 (https=)
DK (1) DK1501809T3 (https=)
EA (1) EA007720B1 (https=)
EC (1) ECSP045391A (https=)
ES (1) ES2298513T3 (https=)
HR (1) HRP20041008B1 (https=)
IL (2) IL164675A0 (https=)
MX (1) MXPA04010622A (https=)
MY (1) MY141559A (https=)
NO (1) NO333647B1 (https=)
NZ (1) NZ535886A (https=)
PE (1) PE20040600A1 (https=)
PL (1) PL212090B1 (https=)
PT (1) PT1501809E (https=)
TW (1) TWI265807B (https=)
UA (1) UA79113C2 (https=)
WO (1) WO2003091226A1 (https=)
ZA (1) ZA200408670B (https=)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR039241A1 (es) 2002-04-04 2005-02-16 Biogen Inc Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos
EP1638944A1 (en) * 2003-06-12 2006-03-29 Eli Lilly And Company Tachykinin receptor antagonists
NZ580480A (en) * 2003-10-24 2010-02-26 Lilly Co Eli Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1H-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
US7820654B2 (en) 2004-09-23 2010-10-26 Dr. Reddy's Laboratories Ltd. Pyrimidine compounds, process for their preparation and compositions containing them
WO2006083711A1 (en) * 2005-02-01 2006-08-10 Eli Lilly And Company Tachykinin receptor antagonists
JP4874958B2 (ja) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピリジン誘導体を含有する抗真菌剤
EP1894919B1 (en) * 2005-06-07 2012-03-28 Shionogi & Co., Ltd. Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity
ES2353724T3 (es) * 2005-07-25 2011-03-04 F. Hoffmann-La Roche Ag Derivados de triazol substitutidos y su uso como antagonistas del receptor neuroquinina 3.
TWI385169B (zh) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd 經雜環取代之吡啶衍生物及含有彼之抗真菌劑
BRPI0621959A2 (pt) * 2006-08-18 2011-12-27 Syngenta Ltd usos de pelo menos um composto capaz de inibir 4-hidroxifenilpiruvato dioxigenase, e de um composto ou uma composiÇço, kit, e, composiÇço farmacÊutica
EP2065377B1 (en) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
CN101568523A (zh) * 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]－吡啶－3－基｝·(2－氯苯基)甲酮的新中间体和方法
EP2185529A1 (en) * 2007-08-08 2010-05-19 NeuroSearch AS Novel 1,2,3-triazole derivatives useful as modulators of nicotinic acetylcholine receptors
GB0722077D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
AU2009263037B2 (en) * 2008-06-26 2011-10-06 Amgen Inc. Alkynyl alcohols as kinase inhibitors
GB0823002D0 (en) * 2008-12-17 2009-01-28 Syngenta Participations Ag Isoxazoles derivatives with plant growth regulating properties
WO2013004766A1 (en) 2011-07-04 2013-01-10 Ferrari Giulio Nk-1 receptor antagonists for treating corneal neovascularisation
TWI636047B (zh) 2013-08-14 2018-09-21 英商卡爾維斯塔製藥有限公司 雜環衍生物
GB201421083D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd Enzyme inhibitors
GB201421085D0 (en) 2014-11-27 2015-01-14 Kalvista Pharmaceuticals Ltd New enzyme inhibitors
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
IL263235B (en) 2016-05-31 2022-07-01 Kalvista Pharmaceuticals Ltd History of pyrazoles as plasma kallikrein inhibitors
GB201609607D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts
GB201609603D0 (en) 2016-06-01 2016-07-13 Kalvista Pharmaceuticals Ltd Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20250140655A (ko) * 2017-11-17 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
HUE057912T2 (hu) 2017-11-29 2022-06-28 Kalvista Pharmaceuticals Ltd Plazma kallikrein inhibitort tartalmazó dózisformák
GB201719881D0 (en) 2017-11-29 2018-01-10 Kalvista Pharmaceuticals Ltd Solid forms of plasma kallikrein inhibitor and salts thereof
CN111918647A (zh) 2018-02-26 2020-11-10 圣拉斐尔医院有限公司 用于治疗眼痛的nk-1拮抗剂
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
KR102863233B1 (ko) * 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
WO2020132513A1 (en) 2018-12-21 2020-06-25 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
WO2021028645A1 (en) 2019-08-09 2021-02-18 Kalvista Pharmaceuticals Limited Plasma kallikrein inhibitors
JP2023515167A (ja) 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021180885A1 (en) 2020-03-11 2021-09-16 Ospedale San Raffaele S.R.L. Treatment of stem cell deficiency
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
AU2021246889A1 (en) 2020-04-03 2022-10-13 Nerre Therapeutics Limited An NK-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ARDS) or multiple organ dysfunction syndrome (MODS)
CN113563306B (zh) * 2020-04-28 2022-07-01 新发药业有限公司 一种2-(4-苯氧基苯基)-6-(哌啶-4-)基烟酰胺的制备方法
CA3177477A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
CN111662235B (zh) * 2020-06-23 2023-12-22 黄淮学院 一种苯甲酰基哒嗪衍生物及其制备方法
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
CN116082253B (zh) * 2023-02-25 2025-04-25 浙大城市学院 一种1-n-取代的1,2,3-三唑-4-甲酰胺衍生物及其制备方法
WO2024223617A1 (en) * 2023-04-24 2024-10-31 Fundamental Pharma Gmbh Effective means to modulate nmda receptor-mediated toxicity
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000068010A (ko) * 1996-07-24 2000-11-25 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 아졸로 트리아진 및 피리미딘

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL50699A0 (en) 1975-10-28 1976-12-31 Ici America Inc Triazole derivatives
AU7947594A (en) * 1993-10-27 1995-05-22 Merck Sharp & Dohme Limited Substituted amides as tachykinin antagonists
US6175013B1 (en) * 1994-06-10 2001-01-16 Eli Lilly And Company Imidazolinyl tachykinin receptor antagonists
US5998444A (en) * 1995-10-24 1999-12-07 Zeneca Ltd. Piperidinyl compounds as NK1 or NK2 antagonists
AU2633897A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Solid phase and combinatorial synthesis of substituted 1,2,3-triazoles and of arrays of substituted 1,2,3-triazoles
US6060478A (en) * 1996-07-24 2000-05-09 Dupont Pharmaceuticals Azolo triazines and pyrimidines
CN1272842A (zh) 1997-08-06 2000-11-08 伊莱利利公司 作为速激肽受体拮抗剂的2－酰氨基丙胺类化合物
ES2258485T3 (es) * 1999-12-17 2006-09-01 Schering Corporation Antagonistas selectivos de neuroquinina.
TWI287003B (en) 2000-07-24 2007-09-21 Hoffmann La Roche 4-phenyl-pyridine derivatives
DE10036818A1 (de) * 2000-07-28 2002-02-07 Solvay Pharm Gmbh Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
JP2002123925A (ja) 2000-10-13 2002-04-26 Fuji Photo Film Co Ltd 磁気記録媒体
BR0309486A (pt) * 2002-04-26 2005-02-09 Lilly Co Eli Composto ou um seu sal farmaceuticamente aceitável, composição farmacêutica, e, método para o tratamento de uma condição associada com um excesso de taquicininas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000068010A (ko) * 1996-07-24 2000-11-25 미리암 디. 메코너헤이, 블레어큐. 퍼거슨 아졸로 트리아진 및 피리미딘

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
특허공개 제2000-0068010호

Also Published As

Publication number Publication date
NZ535886A (en) 2007-07-27
JP4559087B2 (ja) 2010-10-06
UA79113C2 (en) 2007-05-25
TWI265807B (en) 2006-11-11
CY1107221T1 (el) 2012-11-21
BR0309534A (pt) 2005-02-01
AU2003230829B8 (en) 2008-12-11
US20050239786A1 (en) 2005-10-27
NO333647B1 (no) 2013-07-29
MY141559A (en) 2010-05-14
BRPI0309534B8 (pt) 2021-05-25
ECSP045391A (es) 2005-01-03
DE60318697T2 (de) 2009-01-08
TW200306824A (en) 2003-12-01
ZA200408670B (en) 2005-10-26
MXPA04010622A (es) 2005-01-25
EP1501809A1 (en) 2005-02-02
DK1501809T3 (da) 2008-05-13
CN1312136C (zh) 2007-04-25
CA2483159C (en) 2010-08-10
AU2003230829A1 (en) 2003-11-10
KR20040104634A (ko) 2004-12-10
PL212090B1 (pl) 2012-08-31
ES2298513T3 (es) 2008-05-16
PT1501809E (pt) 2008-03-18
HRP20041008A2 (en) 2004-12-31
EA200401431A1 (ru) 2005-06-30
JP2005536458A (ja) 2005-12-02
CR7548A (es) 2006-12-01
BRPI0309534B1 (pt) 2017-11-07
CA2483159A1 (en) 2003-11-06
EP1501809B1 (en) 2008-01-16
EA007720B1 (ru) 2006-12-29
HK1073304A1 (en) 2005-09-30
PE20040600A1 (es) 2004-09-15
HRP20041008B1 (hr) 2012-10-31
DE60318697D1 (de) 2008-03-06
AU2003230829B2 (en) 2008-12-04
AR039329A1 (es) 2005-02-16
NO20045120L (no) 2004-12-07
CN1646502A (zh) 2005-07-27
WO2003091226A1 (en) 2003-11-06
PL373504A1 (en) 2005-09-05
ATE384053T1 (de) 2008-02-15
IL164675A0 (en) 2005-12-18
IL198122A0 (en) 2009-12-24
US7320994B2 (en) 2008-01-22

Similar Documents

Publication Publication Date Title
KR100755577B1 (ko) 타키키닌 수용체 길항제로서의 트리아졸 유도체
JP4895476B2 (ja) タキキニン受容体アンタゴニスト
US11168079B2 (en) Alkene compounds as farnesoid x receptor modulators
US11370785B2 (en) Multicyclic compounds as farnesoid X receptor modulators
CZ286498A3 (cs) Chinoxalindiony, způsob a meziprodukty pro jejich výrobu, jejich použití, farmaceutické kompozice na jejich bázi a způsoby léčení
AU2018360575A1 (en) Alkene spirocyclic compounds as farnesoid X receptor modulators
NO332143B1 (no) Imidazolderivater, fremgangsmate for fremstilling av slike, medikament inneholdende slike, slike forbindelser for anvendelse til behandling av sykdom samt anvendelse av slike for fremstilling av medikamenter for behandling av sykdom
EP4463452B1 (en) C-myc mrna translation modulators and uses thereof in the treatment of cancer
US20220162201A1 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
AU2003224868B8 (en) Tachykinin receptor antagonists
HK1073304B (en) Triazole derivatives as tachykinin receptor antagonists

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20041025

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20050708

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20060721

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20070226

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20060721

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20070529

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20070226

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20070713

Appeal identifier: 2007101005779

Request date: 20070529

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20070529

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20070529

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20061023

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 20050708

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20070713

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20070629

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20070829

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20070829

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20100729

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20110728

Start annual number: 5

End annual number: 5

FPAY Annual fee payment

Payment date: 20120727

Year of fee payment: 6

PR1001 Payment of annual fee

Payment date: 20120727

Start annual number: 6

End annual number: 6

FPAY Annual fee payment

Payment date: 20130812

Year of fee payment: 7

PR1001 Payment of annual fee

Payment date: 20130812

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20140807

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20140807

Start annual number: 8

End annual number: 8

FPAY Annual fee payment

Payment date: 20150807

Year of fee payment: 9

PR1001 Payment of annual fee

Payment date: 20150807

Start annual number: 9

End annual number: 9

FPAY Annual fee payment

Payment date: 20160811

Year of fee payment: 10

PR1001 Payment of annual fee

Payment date: 20160811

Start annual number: 10

End annual number: 10

PC1801 Expiration of term

Termination date: 20231022

Termination category: Expiration of duration